The authors reviewed published studies about the benefits and harms of drugs used to treat depression. The reviewers focused on second-generation antidepressants—bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, sertraline, trazadone, and venlafaxine (generic names).